Nuvectis Pharma
NVCT
8 hedge funds and large institutions have $4.65M invested in Nuvectis Pharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.94% more ownership
Funds ownership: 0% → 4.94% (+4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Ronit Capital
London,
United Kingdom
|
+$3.83M |
| 2 |
Millennium Management
New York
|
+$293K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$103K |
| 4 |
VF
Virtu Financial
New York
|
+$79.1K |
| 5 |
BlackRock
New York
|
+$54.8K |
Top Sellers
NVCT Hedge Fund Activity: Q1 2022 in Review
8 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2022, worth a combined $4.65M.
Buyers outnumbered sellers: 8 funds opened new NVCT positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Ronit Capital, opening a new position worth an estimated $3.83M.
- 8 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $4.65M of Nuvectis Pharma stock for Q1 2022.
- 8 funds opened new Nuvectis Pharma positions in Q1 2022 and 0 closed out, a net change of +8 holders.
- The largest Nuvectis Pharma buyer in Q1 2022 was Ronit Capital, an estimated $3.83M added.
Based on aggregated 13F filings for Q1 2022.